IXICO plc announced that it has been contracted by a top five CRO on behalf of a new pharma client to provide its imaging biomarker services for a Phase 3 clinical trial for patients with a type of Parkinsonian disorder. The trial is due to run for just under 5 years and is worth in excess of £1 million.